MOUD Buprenorphine Sublocade denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for moud buprenorphine sublocade are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Sublocade as Experimental — and Why That Classification Is Wrong

An experimental or investigational denial for Sublocade (extended-release injectable buprenorphine) is almost certainly an administrative error. The FDA granted full approval for Sublocade for the treatment of moderate-to-severe opioid use disorder (OUD) in adults. It is not a clinical trial drug, a compounded formulation, or an off-label use when prescribed for its approved indication. Denying an FDA-approved drug for its labeled indication as "experimental" is a reviewable — and commonly reversed — determination.

## Why This Denial Is Appealable

Federal parity law (the Mental Health Parity and Addiction Equity Act) prohibits insurers from applying more restrictive coverage limitations to substance use disorder treatment than to analogous medical conditions. Labeling an FDA-approved addiction medication as investigational, while covering FDA-approved medications for other chronic conditions without the same classification, is a potential parity violation on top of the substantive coverage error.

## Your Federal Appeal Rights

• Internal appeal: File a written internal appeal under ERISA §503 or ACA §2719. Reference the FDA approval date and the labeled indication directly in your letter.
• External review: Under ACA §2719, you have the right to independent external review after exhausting internal channels — or if the plan misses its internal deadline. The window to request external review is generally up to four months from the internal denial notice; verify the exact date on your letter.
• Expedited appeal: If the patient is at acute risk (e.g., active relapse risk without access to medication), request expedited review with prescriber documentation of urgency.

## Concrete Appeal Steps

1. Obtain the full denial letter and identify the specific policy language used to classify Sublocade as experimental. 2. Download the current FDA prescribing label for Sublocade from the FDA website (Drugs@FDA) — it is your primary evidence that this drug is fully approved for the stated indication. 3. Pull UnitedHealthcare's published coverage policy and locate the experimental/investigational definition. Confirm Sublocade does not meet that definition. 4. Have the prescriber write a letter citing the FDA approval and the applicable ASAM and SAMHSA clinical guidelines for MOUD. 5. Submit the internal appeal with the documentation package below. If denied again, immediately request external review.

## Documentation to Gather

• FDA approval evidence: The prescribing label (package insert) for Sublocade, obtained directly from Drugs@FDA, showing the approved indication.
• Diagnosis confirmation: Documented DSM-5 diagnosis of moderate-to-severe OUD.
• Prescriber medical-necessity letter: Stating the approved indication, noting relevant ASAM/SAMHSA guideline support (by organization name, not numbers), and explicitly refuting the experimental classification.
• Parity argument (if applicable): If your plan covers other FDA-approved chronic-disease maintenance medications without an experimental designation, document that asymmetry.
• Criteria-mapping table: Copy UHC's experimental/investigational criteria from their policy; show in each row that Sublocade does not meet the definition.

## Criteria-Mapping Structure

For each element of UHC's experimental definition (commonly: not FDA-approved for the indication, evidence insufficient, under clinical investigation, etc.), place the counter-evidence in the adjacent column. A well-structured table prevents reviewers from overlooking any element.